EyePoint Pharmaceuticals Accounts Payable

EyePoint Pharmaceuticals (EYPT) currently reports a accounts payable of $17M as of June 2026. That compares with $31M in the prior-year period — down 44.6% year over year. Use the charts on this page to explore EyePoint Pharmaceuticals's accounts payable history and peer comparisons.

EyePoint Pharmaceuticals's accounts payable decreased from $31M to $17M — a 44.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

EyePoint Pharmaceuticals reported $17M in accounts payable as of June 2026. That compares with $31M in the prior-year period — down 44.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for EyePoint Pharmaceuticals, and consider following EYPT for alerts when major investors trade the stock.

EyePoint Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EYPT with unrelated industries.